☆ 4.7 Article

Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

ANNALS OF ONCOLOGY (2011)

期刊

ANNALS OF ONCOLOGY

卷 22, 期 -, 页码 vi59-vi63

出版社

OXFORD UNIV PRESS

DOI: 10.1093/annonc/mdr388

关键词

-

类别

Oncology

资金

Bayer
Mundipharma
Roche
NCI NIH HHS [P01 CA081534] Funding Source: Medline

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Hematology

Long-term follow-up demonstrates curative potential of autologous stem cell transplantation for relapsed follicular lymphoma

Robert Puckrin, Neil Chua, Kelly Chin, Anthea Peters, Peter Duggan, Mona Shafey, Jan Storek, Kareem Jamani, Carolyn Owen, Douglas Stewart

Summary: ASCT demonstrates high rates of durable remission in relapsed FL, with long-term follow-up revealing that more than 50% of transplanted patients may be functionally cured of their lymphoma. The optimal timing to consider ASCT is at first or second relapse, regardless of POD24 status.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

添加到收藏夹

Article Oncology

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer

R. Kanesvaran, E. Castro, A. Wong, K. Fizazi, M. L. K. Chua, Y. Zhu, H. Malhotra, Y. Miura, J. L. Lee, F. L. T. Chong, Y-S Pu, C-C Yen, M. Saad, H. J. Lee, H. Kitamura, K. Prabhash, Q. Zou, G. Curigliano, E. Poon, S. P. Choo, S. Peters, E. Lim, T. Yoshino, G. Pentheroudakis

Summary: To accommodate the specific requirements of prostate cancer treatment in Asia, a special meeting was convened by ESMO and SSO to revise the guidelines published in 2020. These guidelines represent the consensus opinions of prostate cancer treatment experts from Asian countries and aim to provide optimization and harmonization recommendations for the management of prostate cancer patients across different regions in Asia.

ESMO OPEN (2022)

添加到收藏夹

Article Oncology

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer

T. Yoshino, G. Argiles, E. Oki, E. Martinelli, H. Taniguchi, D. Arnold, Mishima, Y. Li, B. K. Smruti, J. B. Ahn, I. Faud, C. E. Chee, K. -h. Yeh, P. -c. Lin, C. Chua, H. H. Hasbullah, M. A. Lee, A. Sharma, Y. Sun, G. Curigliano, H. Bando, F. Lordick, T. Yamanaka, J. Tabernero, E. Baba, A. Cervantes, A. Ohtsu, S. Peters, C. Ishioka, G. Pentheroudakis

Summary: The ESMO 2020 guidelines for localised colon cancer were adapted to account for ethnic differences in Asian patients during a special virtual meeting convened by ESMO and JSMO in March 2021. These guidelines represent the consensus opinions of experts from various oncological societies in Asia, and the voting was based on scientific evidence.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Nine-Year Follow-up of Patients with Relapsed Follicular Lymphoma after Nonmyeloablative Allogeneic Stem Cell Transplant and Autologous Transplant

Issa F. Khouri, Denai R. Milton, Alison M. Gulbis, Elias J. Jabbour, Loretta Nastoupil, Celina Ledesma, Paolo Anderlini, Qaiser Bashir, May Daher, Jin S. Im, Swaminathan P. Iyer, David Marin, Rohtesh S. Mehta, Amanda L. Olson, Uday R. Popat, Muzaffar Qazilbash, Neeraj Saini, Felipe Samaniego, Gabriela Rondon, L. Jeffrey Medeiros, Richard E. Champlin

Summary: In patients with relapsed follicular lymphoma, receiving alloSCT has been shown to confer better overall survival and progression-free survival compared to autoSCT.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Article Oncology

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer

T. Yoshino, A. Cervantes, H. Bando, E. Martinelli, E. Oki, R. -H. Xu, N. A. Mulansari, K. Govind Babu, M. A. Lee, C. K. Tan, G. Cornelio, D. Q. Chong, L. -T. Chen, S. Tanasanvimon, N. Prasongsook, K. -H. Yeh, C. Chua, M. D. Sacdalan, W. J. Sow (Jenson), S. T. Kim, R. T. Chacko, R. A. Syaiful, S. Z. Zhang, G. Curigliano, S. Mishima, Y. Nakamura, H. Ebi, Y. Sunakawa, M. Takahashi, E. Baba, S. Peters, C. Ishioka, G. Pentheroudakis

Summary: The ESMO Guidelines for metastatic colorectal cancer (mCRC) were adapted to produce the Pan-Asian adapted (PAGA) ESMO consensus guidelines for Asian patients. The guidelines were developed by a panel of experts from Asian oncological societies, based on scientific evidence and independent of treatment practices and reimbursement decisions. The aim is to optimize and harmonize the management of mCRC across Asia, considering the differences in screening practices, molecular profiling, and drug approvals and reimbursement strategies.

ESMO OPEN (2023)

添加到收藏夹

Article Oncology

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma

R. Kanesvaran, C. Porta, A. Wong, T. Powles, Q. S. Ng, M. Schmidinger, D. Ye, H. Malhotra, Y. Miura, J. L. Lee, F. L. T. Chong, Y-S Pu, C-C Yen, M. Saad, H. J. Lee, H. Kitamura, G. S. Bhattacharyya, G. Curigliano, E. Poon, S. P. Choo, S. Peters, E. Lim, T. Yoshino, G. Pentheroudakis

Summary: The ESMO and SSO held a special virtual guidelines meeting in May 2021 to adapt the 2019 guidelines for renal cell carcinoma treatment to account for ethnic differences in Asian patients. Expert opinions from oncological societies in China, India, Japan, Korea, Malaysia, Singapore, and Taiwan were considered based on scientific evidence independent of current treatment practices and drug access restrictions in Asian countries.

ESMO OPEN (2021)

添加到收藏夹

Article Medicine, General & Internal

Follicular Lymphoma-Diagnosis, Treatment, and Follow-Up

Anna Zoellner, Klaus Herfarth, Michael Herold, Wolfram Klapper, Nicole Skoetz, Wolfgang Hiddemann

Summary: Follicular lymphoma primarily affects elderly individuals, with treatment options including radiotherapy, chemotherapy, or maintenance therapy depending on the severity of the disease. Thorough follow-up is necessary to detect late complications such as second malignancies or organ damage.

DEUTSCHES ARZTEBLATT INTERNATIONAL (2021)

添加到收藏夹

Article Oncology

Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up

S. J. Strauss, A. M. Frezza, N. Abecassis, J. Bajpai, S. Bauer, R. Biagini, S. Bielack, J. Y. Blay, S. Bolle, S. Bonvalot, I Boukovinas, J. V. M. G. Bovee, K. Boye, B. Brennan, T. Brodowicz, A. Buonadonna, E. de Alava, A. P. Dei Tos, X. Garcia Del Muro, A. Dufresne, M. Eriksson, F. Fagioli, A. Fedenko, V Ferraresi, A. Ferrari, N. Gaspar, S. Gasperoni, H. Gelderblom, F. Gouin, G. Grignani, A. Gronchi, R. Haas, A. B. Hassan, S. Hecker-Nolting, N. Hindi, P. Hohenberger, H. Joensuu, R. L. Jones, C. Jungels, P. Jutte, L. Kager, B. Kasper, A. Kawai, K. Kopeckova, D. A. Krakorova, A. Le Cesne, F. Le Grange, E. Legius, A. Leithner, A. Lopez Pousa, J. Martin-Broto, O. Merimsky, C. Messiou, A. B. Miah, O. Mir, M. Montemurro, B. Morland, C. Morosi, E. Palmerini, M. A. Pantaleo, R. Piana, S. Piperno-Neumann, P. Reichardt, P. Rutkowski, A. A. Safwat, C. Sangalli, M. Sbaraglia, S. Scheipl, P. Schoffski, S. Sleijfer, D. Strauss, K. Sundby Hall, A. Trama, M. Unk, M. A. J. van de Sande, W. T. A. van der Graaf, W. J. van Houdt, T. Frebourg, R. Ladenstein, P. G. Casali, S. Stacchiotti

Summary: The paragraph lists the names of various researchers, possibly in the author list of a research paper.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis

Yuqin Song, Quanli Gao, Huilai Zhang, Lei Fan, Jianfeng Zhou, Dehui Zou, Wei Li, Haiyan Yang, Ting Liu, Quanshun Wang, Fangfang Lv, Haiyi Guo, Xia Zhao, Dan Wang, Pei Zhang, Yidi Wang, Lei Wang, Tengfei Liu, Yun Zhang, Zhirong Shen, Jane Huang, Jun Zhu

Summary: This study presents the extended 3-year follow-up of tislelizumab in patients with relapsed/refractory cHL, showing long-term benefits and a favorable safety profile.

CLINICAL CANCER RESEARCH (2022)

添加到收藏夹

Article Hematology

Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma

Philippe Armand, Pier Luigi Zinzani, Hun Ju Lee, Nathalie A. Johnson, Pauline Brice, John Radford, Vincent Ribrag, Daniel Molin, Theodoros P. Vassilakopoulos, Akihiro Tomita, Bastian von Tresckow, Margaret A. Shipp, Alex F. Herrera, Jianxin Lin, Eunhee Kim, Samhita Chakraborty, Patricia Marinello, Craig H. Moskowitz

Summary: This study demonstrates that Pembrolizumab provides durable antitumor activity in patients with relapsed or refractory classical Hodgkin lymphoma, and a second course of treatment can reinduce sustained responses after relapse from initial complete response.

BLOOD (2023)

添加到收藏夹

Article Nutrition & Dietetics

The prognostic nutritional index, an independent predictor of overall survival for newly diagnosed follicular lymphoma in China

Jingjing Ge, Yaxin Lei, Qing Wen, Yue Zhang, Xiaoshuang Kong, Wenhua Wang, Siyu Qian, Huting Hou, ZeYuan Wang, Shaoxuan Wu, Meng Dong, Mengjie Ding, Xiaolong Wu, Xiaoyan Feng, Linan Zhu, Mingzhi Zhang, Qingjiang Chen, Xudong Zhang

Summary: The study aimed to explore the predictive value of prognostic nutritional index (PNI) in newly diagnosed follicular lymphoma (FL) in China. The results showed that PNI could predict survival outcomes in FL patients and was the only independent predictor of overall survival (OS). Integrating PNI into other models improved the accuracy of survival prediction.

FRONTIERS IN NUTRITION (2022)

添加到收藏夹

Article Biophysics

Durable benefit of rituximab maintenance post-autograft in patients with relapsed follicular lymphoma: 12-year follow-up of the EBMT lymphoma working party Lym1 trial

R. Pettengell, R. Uddin, A. Boumendil, R. Johnson, B. Metzner, A. Martin, J. Romejko-Jarosinska, I Bence-Bruckler, P. Giri, C. U. Niemann, S. P. Robinson, E. Kimby, N. Schmitz, P. Dreger, A. H. Goldstone, S. Montoto

Summary: The study showed that rituximab maintenance therapy continues to benefit patients with relapsed follicular lymphoma undergoing autologous stem cell transplant by improving progression-free survival after 10 years, indicating that it enhances the curative potential of ASCT without significantly affecting overall survival.

BONE MARROW TRANSPLANTATION (2021)

添加到收藏夹

Article Oncology

Pan-Asian adaptation of the EHNS-ESMO-ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck

B. Keam, J-P Machiels, H. R. Kim, L. Licitra, W. Golusinski, V Gregoire, Y. G. Lee, C. Belka, Y. Guo, S. J. Rajappa, M. Tahara, M. Azrif, M. K. Ang, M-H Yang, C-H Wang, Q. S. Ng, W. I. Wan Zamaniah, N. Kiyota, S. Babu, K. Yang, G. Curigliano, S. Peters, T. W. Kim, T. Yoshino, G. Pentheroudakis

Summary: ESMO and KSMO convened a special virtual guidelines meeting in July 2021 to adapt the ESMO 2020 guidelines to consider potential ethnic differences in Asian patients' treatment of SCCs of the head and neck. These guidelines represent consensus opinions from experts across Asia and provide expert recommendations for the diagnosis, treatment, and management of patients with SCC of the oral cavity, larynx, oropharynx, and hypopharynx.

ESMO OPEN (2021)

添加到收藏夹

Article Oncology

Treatment selection for patients with relapsed or refractory follicular lymphoma

Alan Z. Skarbnik, Krish Patel

Summary: Follicular lymphoma (FL) is a common lymphoma with a variable clinical course. The response to treatment decreases with each line of therapy, and poor survival outcomes are associated with disease progression within 24 months of initial treatment. Although rituximab-based regimens are preferred for early lines of treatment, there is no clear standard of care for third-line treatment or later.

FRONTIERS IN ONCOLOGY (2023)

添加到收藏夹

Article Biochemistry & Molecular Biology

Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial

Nathan Hale Fowler, Michael Dickinson, Martin Dreyling, Joaquin Martinez-Lopez, Arne Kolstad, Jason Butler, Monalisa Ghosh, Leslie Popplewell, Julio C. Chavez, Emmanuel Bachy, Koji Kato, Hideo Harigae, Marie Jose Kersten, Charalambos Andreadis, Peter A. Riedell, P. Joy Ho, Jose Antonio Perez-Simon, Andy Chen, Loretta J. Nastoupil, Bastian von Tresckow, Andres Jose Maria Ferreri, Takanori Teshima, Piers E. M. Patten, Joseph P. McGuirk, Andreas L. Petzer, Fritz Offner, Andreas Viardot, Pier Luigi Zinzani, Ram Malladi, Aiesha Zia, Rakesh Awasthi, Aisha Masood, Oezlem Anak, Stephen J. Schuster, Catherine Thieblemont

Summary: Tisagenlecleucel, an autologous anti-CD19 CAR-T cell therapy, demonstrated a high complete response rate of 69.1% and overall response rate of 86.2% in adults with relapsed or refractory follicular lymphoma. Adverse events post-treatment primarily included cytokine release syndrome and neurological events, with no treatment-related deaths reported.

NATURE MEDICINE (2022)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 1-Clinical)

Fabien Ricard, Bruce Cheson, Sally Barrington, Judith Trotman, Annette Schmid, Guenther Brueggenwerth, Gilles Salles, Larry Schwartz, Greg Goldmacher, Rudresh Jarecha, Jayant Narang, Florence Broussais, Paul Galette, Min Liu, Surabhi Bajpai, Eric Perlman, Julie Gillis, Ira Smalberg, Pierre Terve, Gudrun Zahlmann, Ron Korn

Summary: This article presents consensus recommendations on the consistent application of the Lugano classification in the field of lymphoma and imaging. The recommendations were obtained through meetings involving academic and industry experts and provide updates and clarifications on the technical considerations and scoring guidelines of the Lugano classification. These consensus recommendations aim to address inconsistencies and ambiguities encountered by end users during response evaluation and should be used alongside the 2014 Lugano classification as a companion guide.

JOURNAL OF NUCLEAR MEDICINE (2023)

添加到收藏夹

Review Hematology

Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities

Lorenzo Falchi, Santosha A. Vardhana, Gilles A. Salles

Summary: Treatment paradigms for B-cell non-Hodgkin lymphomas (B-NHL) have undergone significant changes in the past two decades due to the introduction of highly active immunotherapies. Bispecific antibodies (BsAb) have emerged as a promising immunotherapeutic for B-NHL, with anti-CD20xCD3 BsAb showing remarkable single-agent activity. However, further research is needed to determine the optimal deployment of these drugs, ideal combination partners, strategies for minimizing toxicity, and pharmacodynamic biomarkers of response and resistance.

BLOOD (2023)

添加到收藏夹

Review Hematology

Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study

Georg Hess, Martin Dreyling, Lucie Oberic, Eva Gine, Pier Luigi Zinzani, Kim Linton, Adam Vilmar, Mats Jerkeman, Jenny M. H. Chen, Anke Ohler, Stephan Stilgenbauer, Catherine Thieblemont, Jonathan Lambert, Vittorio Ruggero Zilioli, Juan-Manuel Sancho, Ana Jimenez Ubieto, Luca Fischer, Toby A. Eyre, Sam Keeping, Julie E. Park, James J. Wu, Rubina Siddiqi, John Reitan, Sally Wade, Gilles Salles

Summary: Relapsed Mantle cell lymphoma (MCL) has a poor prognosis and there is no standard treatment. This study examined the outcomes of salvage therapy in MCL patients who failed Bruton tyrosine kinase inhibitor (BTKi) therapy, showing shorter overall survival in this group compared to those who received post-BTKi therapy.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

添加到收藏夹

Letter Oncology

Molecular remission is an independent predictor of progression-free survival in patients with Waldenstrom macroglobulinemia treated with chemo-immunotherapy: Results from the FIL_BIOWM study

Marzia Varettoni, Silvia Zibellini, Michele Merli, Daniela Drandi, Cristina Jimenez, Daniela Furlan, Virginia Valeria Ferretti, Nicole Fabbri, Irene Dogliotti, Chiara Varraso, Martina Ferrante, Emilia Cappello, Veronica Peri, Chiara Cavalloni, Michela Borriero, Giulia Vittoria Facchetti, Simone Ferrero, Luca Arcaini, Ramon Garcia-Sanz

HEMATOLOGICAL ONCOLOGY (2023)

添加到收藏夹

Article Oncology

SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort

Michele Merli, Isacco Ferrarini, Francesco Merli, Alessandro Busca, Roberto Mina, Brunangelo Falini, Riccardo Bruna, Roberto Cairoli, Monia Marchetti, Alessandra Romano, Michele Cavo, Luca Arcaini, Livio Trentin, Chiara Cattaneo, Enrico Derenzini, Nicola Stefano Fracchiolla, Francesco Marchesi, Annamaria Scattolin, Atto Billio, Monica Bocchia, Massimo Massaia, Carlo Gambacorti-Passerini, Francesca Romana Mauro, Massimo Gentile, Sara Mohamed, Matteo Giovanni Della Porta, Elisa Coviello, Daniela Cilloni, Giuseppe Visani, Augusto Bramante Federici, Maria Chiara Tisi, Laura Cudillo, Sara Galimberti, Filippo Gherlinzoni, Livio Pagano, Anna Guidetti, Lorenza Bertu, Paolo Corradini, Francesco Passamonti, Carlo Visco

Summary: A study analyzed data from CLL patients with COVID-19 in Italy and found that male sex, age over 70, recent CLL treatment, and COVID-19 severity were independently associated with poor survival. The study revealed a dismal COVID-related outcome in a significant fraction of CLL patients.

HEMATOLOGICAL ONCOLOGY (2023)

添加到收藏夹

Article Hematology

Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms

Christian Pecquet, Nicolas Papadopoulos, Thomas Balligand, Ilyas Chachoua, Amandine Tisserand, Audrey Nedelec, Didier Vertommen, Anita Roy, Caroline Marty, Harini Nivarthi, Mira El-Khoury, Eva Hug, Andrea Majoros, Erica Xu, Oleh Zagrijtschuk, Tudor E. Fertig, Daciana S. Marta, Heinz Gisslinger, Bettina Gisslinger, Martin Schalling, Ilaria Casetti, Elisa Rumi, Daniela Pietra, Chiara Cavalloni, Luca Arcaini, Mario Cazzola, Norio Komatsu, Yoshihiko Kihara, Yoshitaka Sunami, Yoko Edahiro, Marito Araki, Roman Lesyk, Veronika Buxhofer-Ausch, Sonja Heibl, Florence Pasquier, Violaine Havelange, Isabell Plo, William Vainchenker, Robert Kralovics, Stefan N. Constantinescu

Summary: Mutant CALR proteins bind to and activate the TpoR in cells, driving the development of myeloproliferative neoplasms. These mutant CALR proteins can be found in patient plasma complexed with sTFR1, which increases their stability. They can specifically interact with TpoR on target cells and promote thrombopoietin-independent colony formation.

BLOOD (2023)

添加到收藏夹

Article Oncology

High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network

Olivier Hermine, Linmiao Jiang, Jan Walewski, Andre Bosly, Catherine Thieblemont, Michal Szymczyk, Christiane Pott, Gilles Salles, Pierre Feugier, Kai Hubel, Corinne Haioun, Rene Olivier Casasnovas, Christian Schmidt, Kamal Bouabdallah, Vincent Ribrag, Lothar Kanz, Jan Durig, Bernd Metzner, David Sibon, Morgane Cheminant, Barbara Burroni, Wolfram Klapper, Wolfgang Hiddemann, Michael Unterhalt, Eva Hoster, Martin Dreyling

Summary: Clinical Trial Updates provide an opportunity to disseminate additional results from studies for which the primary end point has already been reported. This study confirms the previously observed substantially prolonged time to treatment failure and shows an improvement in overall survival for patients with Mantle Cell Lymphoma. Some patients with MCL may be cured.

JOURNAL OF CLINICAL ONCOLOGY (2023)

添加到收藏夹

Article Medicine, General & Internal

Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK Inhibitors

Francesca Guidetti, Alberto J. Arribas, Giulio Sartori, Filippo Spriano, Laura Barnabei, Chiara Tarantelli, Reinhard Von Roemeling, Elizabeth Martinez, Emanuele Zucca, Francesco Bertoni

Summary: Inhibitors of PI3K and BTK have limited success in inducing complete responses in indolent B cell lymphomas, suggesting the need for combination therapies. The IRAK4 inhibitor emavusertib shows effectiveness as a single agent and in combination with targeted agents, including overcoming resistance to BTK and PI3K inhibitors. Emavusertib exerts its activity through inhibition of NF-kappa B signaling and induction of apoptosis.

JOURNAL OF CLINICAL MEDICINE (2023)

添加到收藏夹

Article Hematology

Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular Lymphoma

Reid W. Merryman, Laure Michaud, Robert Redd, Patrizia Mondello, Hyesun Park, Gabriela Spilberg, Matthew Robertson, Eleanor Taranto, Gulrayz Ahmed, Matthew Chase, Erin Jeter, Inhye E. Ahn, Jennifer R. Brown, Jennifer Crombie, Matthew S. Davids, David C. Fisher, Eric Jacobsen, Caron A. Jacobson, Austin I. Kim, Ann S. LaCasce, Samuel Y. Ng, Oreofe O. Odejide, Erin M. Parry, Gilles Salles, Andrew D. Zelenetz, Philippe Armand, Heiko Schoeder, Heather Jacene

Summary: This study found that interim PET scans after 2-4 cycles of frontline chemoimmunotherapy can predict progression-free survival in follicular lymphoma patients, and may be used as a tool for response-adapted treatment strategies.

HEMASPHERE (2023)

添加到收藏夹

Editorial Material Oncology

Promoting Early Radiation Research Exposure Through the Royal College of Radiologists' Summer Undergraduate Research Fellowship

C. M. Jones, A. Choudhury, P. J. Hoskin

CLINICAL ONCOLOGY (2023)

添加到收藏夹

Article Oncology

Functional Magnetic Resonance Imaging in Cervical Cancer Diagnosis and Treatment

M. Abdul-Latif, H. Tharmalingam, Y. Tsang, P. J. Hoskin

Summary: Cervical Cancer is the fourth most common cancer in women worldwide, and there is a need for predictive and prognostic biomarkers to identify populations at risk of poorer treatment response and survival. Magnetic resonance imaging (MRI) is routinely used in cervical cancer and has the potential to provide biomarkers. However, most studies focus on single MRI techniques, highlighting the need for combined approaches to better characterize tumors and identify biomarkers.

CLINICAL ONCOLOGY (2023)

添加到收藏夹

Article Biochemistry & Molecular Biology

Hypoxia Is Associated with Increased Immune Infiltrates and Both Anti-Tumour and Immune Suppressive Signalling in Muscle-Invasive Bladder Cancer

Vicky Smith, Dave Lee, Mark Reardon, Rekaya Shabbir, Sudhakar Sahoo, Peter Hoskin, Ananya Choudhury, Timothy Illidge, Catharine M. L. West

Summary: Hypoxia and suppressive TME are negative prognostic factors for MIBC. Transcriptomic analyses show that hypoxia increases immune signalling and infiltrates in bladder cancer. This study investigates the relationship between HIF-1 and -2, hypoxia, immune signalling, and infiltrates in MIBC.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

添加到收藏夹

Article Biochemistry & Molecular Biology

T-Cells Subsets in Castleman Disease: Analysis of 28 Cases Including Unicentric, Multicentric and HHV8-Related Clinical Forms

Sara Fraticelli, Marco Lucioni, Giuseppe Neri, Deborah Marchiori, Caterina Cristinelli, Michele Merli, Rodolfo Monaco, Tiziana Borra, Antonio Lazzaro, Silvia Uccella, Luca Arcaini, Marco Paulli

Summary: Castleman disease (CD) is a rare lymphoproliferative disorder with various clinico-pathological subtypes. The pathogenesis of CD is still uncertain, but alterations in T-cell subsets may contribute to the development of CD. In this study, the distribution of T-cell subsets in the clinico-pathological spectrum of CD was investigated. The results showed decreased CD4/CD8 ratio and lower number of FOXP3+ T-reg cells in CD cases compared to non-specific reactive lymph nodes.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

添加到收藏夹

Editorial Material Hematology

Deciphering molecular complexity of HCV-associated lymphoproliferation

Michele Merli, Francesco Passamonti, Luca Arcaini

Summary: Recent clinical studies have shown that patients with Hepatitis C virus-associated indolent lymphoproliferative disorders (LPD) can achieve lymphoma responses when treated solely with direct-acting antivirals (DAAs). However, the molecular mechanisms underlying LPD responses to DAAs are not well understood. In this paper, the authors provide new molecular insights, reporting intraclonal diversification and persistence of B-cell clones in most cases, even after viral eradication and positive clinical outcomes. These findings suggest that achieving a molecular response may not be necessary for a 'functional cure' in these patients. Further immunogenetic and mutational studies are needed to better understand this biological puzzle and refine treatment strategies.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

添加到收藏夹

Article Oncology

Bladder-Sparing Treatment With Radical Dose Radiotherapy Is an Effective Alternative to Radical Cystectomy in Patients With Clinically Node-Positive Nonmetastatic Bladder Cancer

Martin Swinton, Neethu Billy Graham Mariam, Jean Ling Tan, Katherine Murphy, Thiraviyam Elumalai, Manjusha Soni, Alexandra Ferrera, Charlotte Richardson, Richard Walshaw, Hitesh Mistry, Vijay Ramani, Yeepei Song, Alison Birtle, Ann Henry, Joachim Chan, Peter Hoskin, Ananya Choudhury

Summary: This study analyzed the survival outcomes of node-positive bladder cancer patients and found that there was no significant difference in survival rates between surgery and radiation therapy. Bladder-sparing treatment should be considered as an option for patients with poor survival rates.

JOURNAL OF CLINICAL ONCOLOGY (2023)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.